Search
Memorial Sloan Kettering researchers have found why certain drugs are not sufficiently effective in treating leukemias called myeloproliferative neoplasms.
Alexander Rudensky’s research focuses on the role of a subset of white blood cells called regulatory T cells, which are believed to suppress the immune system’s ability to fight tumors.
A new strategy for treating pediatric cancers involves preventing cells from repairing their own DNA.
A study of one patient’s disease has clarified why tumors stop responding to a class of experimental drugs called PI3K inhibitors.
Memorial Sloan Kettering researchers have used genetically modified immune cells to eradicate cancer in five patients with acute lymphoblastic leukemia.
In February, Harold Varmus' memoir about his life in science was published.
An international group of investigators led by scientists at Memorial Sloan Kettering Cancer Center and the National Cancer Institute has identified a new genetic marker of risk for breast cancer. Women with this DNA variation are at a 1.4 times greater risk of developing breast cancer compared to those without the variation.
Clues emerge about why promising new breast cancer drugs sometimes don’t work — and what might be done about it.
The presence of inflammatory molecules in the cerebrospinal fluid appears to be causing many of the neurologic effects seen in people with COVID-19.
Gerstner Sloan Kettering recognizes student research by annually awarding the Grayer Fellowships, the Olayan Fellowship, the Robert B. Catell Fellowship, the Palestin Fellowship, and the Geoffrey Beene Graduate Student Fellowships.